Mira Pharmaceuticals (MIRA) Other Non-Current Assets (2023)
Mira Pharmaceuticals' (MIRA) quarterly Other Non-Current Assets came in at $3.5 million in Q4 2023, little changed quarter-over-quarter from $3.5 million in Q3 2023.
Mira Pharmaceuticals (MIRA) Other Non-Current Assets (2023) Analysis & Trends
Mira Pharmaceuticals has disclosed Other Non-Current Assets across 1 years of filings, most recently posting $3.5 million for Q4 2023.
- Other Non-Current Assets for Q4 2023 came in at $3.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $3.5 million (changed N/A YoY), and the FY2023 annual result was $3.5 million, changed N/A from the prior year.
- Other Non-Current Assets came in at $3.5 million for Q4 2023 at Mira Pharmaceuticals, roughly flat from $3.5 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $3.5 million in Q2 2023 to a low of $3.5 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 3.18 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.23 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 14.11 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 10.54 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 6.08 Bn |
| 10 | Mira Pharmaceuticals | 23.69 Mn | 12.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 3.50 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Jun 30, 2023 | 3.50 Mn |